All in one place
Investment Round 2023
Fast Delivery of Investor Updates and Support
- Get wholesale investor pack now
- Meet the founder
- Sign CDA and access Data Room
- Complete due diligence
- Close the deal
NZ$ 2.5M Bridge Round
NZ$ 0.5M Committed Funding
Lentivirus Manufacturing in APAC
Updated August 2023
Cell and Gene Therapy Market
NZ$ 30.8B in 2022
NZ$ 115.1B by 2030
Updated August 2023
Use of Funds
Secure a GMP facility for clinical grade production, improve the yield, onboard customers for 2024 production.
Living without cancer
With our partners we are aiming to make significant strides towards a world with effective and affordable cancer treatment.
With few month's to live David was lucky enough to receive CAR-T therapy treatment in time. Watch his journey and how cell therapy saved his life.
Watch David on TEDx
Instant result: No more cancer has been detected after chemo left David few month's to live.
"I am very lucky"
The journey became an experience that David loves to share. "The cost of treatment has to come down".
To Market Strategy
We use some of the most advanced AI and customer engagement products available to make each customer interaction efficient and meet our customers' requirements with greater accuracy.
Every website visitor has an intent. Through segmentation we understand that intent and are able to deliver what is required for each customer to do business with us.
100% Market Reach
We use AI and traditional methods to identify ideal customers and engage them in personal and customized conversations.
A/B Testing & Smart Segmentation
With every step through our online visitor journey we understand more about our customers. Each click helps us to record preferences and use them to deliver relevant and accurate information in record time.
- HubSpot CRM
- HubSpot CMS
- Chat GPT-4
- ChatSpot AI
- Bing Image AI
- Vidyo AI
- Google Analytics
Lentiviral Vectors play an extremely important role in CAR-T therapy
There are 15 approved cell and gene therapies, eight of which use lentiviral vectors. With our network and partners within immunotherapy and biotech, we aim to transform the future of healthcare and provide easy access and affordable treatments to patients. Join us on our journey.
How it works
Immunotherapy activates the body's immune system to target and eliminate cancer cells, offering new hope for patients. CAR-T therapy genetically modifies patient's T cells to better recognize and destroy cancer cells. This groundbreaking approach has the potential to transform cancer treatment.
Lentiviral vectors are crucial in CAR-T therapy, facilitating T-cell transformation. They enable efficient gene transfer, stable expression in non-dividing cells, and accommodate complex CAR genes while minimizing immune reactions.
Eight FDA-approved LVV-based CGT include Kymriah, Yescarta, Tecartus, Breyanzi, Abecma, Carvykti, Zynteglo, and Skysona. Several CAR-T therapies in clinical trials aim to target different antigens and improve specificity and side effects.
- Efficient Gene Transfer
- Integration into the bodies own genome
- Ability to Transduce Non-Dividing Cells
- Large Packaging Capacity
- Reduced Immunogenicity
- Reduced tariffs among member countries
- Enhanced intellectual property rights
- Regulatory coherence streamline regulations among member countries
- Easier access to markets of all member countries
- Supply chain efficiency
- Provisions that protect foreign investment
- Higher labor and environmental standards
We are looking for Investors that consider adding a promising Biotech CDMO startup with purpose and a high growth potential to their portfolio.
We are located in New Zealand, a country with a highly skilled workforce, supportive government, favorable regulatory environment and strong economy.